Prevalence and clinical impact of Streptococcus pneumoniae nasopharyngeal carriage in solid organ transplant recipients

Table 4 In vitro activities of 11 antibiotics against S. pneumoniae clinical isolates from SOT recipients

Antibiotic	CLSI breakpoints^a (% of isolates)			PK/PD
Antibiotic	Susceptible	Intermediate	Resistant	Susceptibility (% of isolates)	Breakpoint (μg/ml)
O. Penicillin	39.39	51.52	9.09	39.39	≤0.06
I. Penicillin	100	0	0	100	≤2
Amoxicillin	87.88	9.09	3.03	87.88	≤2
Cefotaxime	100	0	0	100	≤1
Ceftriaxone	96.97	3.03	0	96.97	≤1
Azithromycin	53.03	16.67	30.30	53.03	≤0.5
Erythromycin	66.67	3.03	30.30	66.67	≤0.25
Clarithromycin	71.21	0	28.79	71.21	≤0.25
Levofloxacin	75.76	24.24	0	75.76	≤2
Vancomycin	100	0	0	100	≤1
Trimethoprim-sulfamethoxazole	53.03	16.67	30.30	53.03	≤0.5

Abbreviations: O oral, I intravenous
^aThe CLSI breakpoints used were ≤ 0.06 mg/L (susceptible), 0.12 to 1 mg/L (intermediate), and ≥ 2 mg/L (resistant) for oral penicillin and ≤ 2 mg/L (susceptible), 4 mg/L (intermediate), and ≥ 8 mg/L (resistant) for intravenous penicillin; ≤2 mg/L (susceptible), 4 mg/L (intermediate), and ≥ 8 mg/L (resistant) for amoxicillin; ≤1 mg/L (susceptible), 2 mg/L (intermediate), and ≥ 4 mg/L (resistant) for cefotaxime and ceftriaxone; ≤0.5 mg/L (susceptible), 1 mg/L (intermediate), and ≥ 2 mg/L (resistant) for azithromycin; ≤0.25 mg/L (susceptible), 0.5 mg/L (intermediate), and ≥ 1 mg/L (resistant) for erythromycin and clarithromycin; ≤2 mg/L (susceptible), 4 mg/L (intermediate), and ≥ 8 mg/L (resistant) for levofloxacin; ≤1 mg/L (susceptible) for vancomycin; and ≤ 0.5 mg/L (susceptible), 1–2 mg/L (intermediate), and ≥ 4 mg/L (resistant) for trimethoprim-sulfamethoxazole

ISSN: 1471-2334